UNSPSC 51262201: Piperoxan

This classification denotes an alpha-adrenergic blocking agent with the molecular formula C14H19NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9ZCS27634Y, chemically known as 1,4-benzodioxane, 2-(piperidinomethyl)- but generally known as piperoxan, which bears US NIH Compound Identifier 6040. European Medicines Agency schedules Piperoxan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09872MIG. The term PIPEROXAN is an International Non-Proprietary Name.

UNSPSC 51262201 Piperoxan (Commodity) covers pharmaceutical products and related systems that state and local governments procure for public health and emergency response programs. Recent solicitations show activity centered on naloxone (Narcan) and drug deactivation systems, which counties and state health agencies buy to support overdose prevention, community health initiatives, and pharmacy benefit management programs. The issuing bodies include county health departments and state health and human services commissions pursuing these acquisitions through competitive bidding and market research mechanisms.

Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, with a response deadline of July 26, 2023 and potentially FEMA-funded compliance requirements. Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs that would bypass traditional pharmacy benefit managers, with an April 3, 2026 response deadline. Geographic activity centers on Florida and Texas, with the Texas procurement representing exploratory state-level market research rather than immediate contract award, while the Seminole County opportunity reflects operational demand for established naloxone and drug deactivation products with fixed two-year initial terms and one-year renewal options.